FDA’s Post

View organization page for FDA, graphic

742,459 followers

In this CDER Conversation, Dr. Robert Ball, Deputy Director, Office of Surveillance & Epidemiology, explains the Emerging Drug Safety Technology Meeting (EDSTM) program and the application of artificial intelligence (AI) in pharmacovigilance: https://lnkd.in/eRg7K7GB

  • Graphic with abstract blue background.  Photo of Robert Ball, Deputy Director, Office of Surveillance & Epidemiology. Text includes: CDER Conversation with Robert Ball. Small FDA Logo in bottom right corner.
Olutoun S.

Public Health Leader | Program Manager (Vaccine Academy) | Managing Partner, Pharmamed Spectrum Care (Shea Butter Skincare) | Pharmacist | Healthcare Mentor (PIH, IPSF-AfRO) | Ex- USAID/USP Consultant | MBA (LBS)

1w

It's interesting to see this highlights the critical role of innovation in safeguarding public health. Collaboration between regulators and industry leaders creates an optimal pathway and ensures patients have access to safe and effective medicines.

Like
Reply
Lisa Bollinger (Mathis)

Bollinger Regulatory Consulting

1w

Way to go! This is real progress. Congratulations!

Like
Reply
Ravi Patel, RPh, PharmD, MBA

Senior VP, Executive Bio-Pharma Leader, Builder, Optimizer & Super-connector with responsibility of Global Patient Safety & Quality Compliance at United Therapeutics Corp.

1w

Looking forward to your talk Bob! Much needed🤖

Like
Reply
Aloka Chakravarty

VP, Head of Enterprise RWE (I&I, IM), Pfizer

1w

Insightful!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics